View Cart  

UCB to File for Two More Cimzia Arthritis Indications This Year, Tables Another RA Candidate

A A
UCB plans to submit marketing applications for Cimzia in psoriatic arthritis and axial spondyloarthritis (AxSpA), including ankylosing spondylitis, to the FDA and EU by the end of the year.

To View This Article:

Login

Subscribe To Drug Industry Daily